António Parada is a biologist, graduated at the University of Porto, Portugal. He joined Bial as a pre-clinical pharmacologist. In the same company, he was appointed to the team that managed the pre-clinical and clinical development of anti-parkinson and anti-convulsant (Zebinix) New Chemical Entities projects. After its MBA at the Portuguese Catholic University he setup and managed the technology transfer office at IBMC with licensing deals across Europe and USA. He was also the General Manager of IBMC. He was vice-president of the European Association of technology transfer, responsible for setting up the first European Technology transfer training courses. He founded the Biocodex group and left after six years with a turnover of 10 million Euros. He was the Porto site manager of the “Centre of Excellence in phage display” of Ablynx. He was the Manager of the Clinical Trial Unit of IPO Porto – cancer Hospital. He is a Member of the Supervisory Board of EMBLEM. He is a Board Member at CDEMAC and the CEO of Fairjourney Biologics. He has 15 publications in peer reviewed journals on pharmacology and several others in botany, management, marketing and security.
CSO of FairJourney Biologics
Since 2012 Maria Gonzalez-Pajuelo is co-founder and Chief Scientific Officer at FairJourney Biologics. Maria initiated her career in the monoclonal antibody field in 2006 at Ablynx, where she worked on the discovery and engineering of Nanobodies® as Scientist-Team leader until 2012. Maria is co-inventor in 13 patent applications on antibodies and on antibodies technologies and co-author on 13 Peer Reviewed Publications.
CSO of IONTAS
John was the pioneer and inventor of antibody-phage display and co-founder of Cambridge Antibody Technology which was subsequently acquired by MedImmune.
On leaving CAT, John established a highly proficient proteomics group at the Wellcome Trust Sanger Institute which developed cutting edge protein expression and high throughput recombinant antibody isolation.
More recently he headed a research group within the Department of Biochemistry, University of Cambridge focused on identifying anti-receptor antibodies with therapeutic potential in cancer indications.